Antoine Francis: Rethinking the Global Plasma Debate — Prioritizing Patients Over Politics
Antoine Francis, Founder of Global Plasma Supply LTD, has shared a post on LinkedIn:
“The global plasma chain is full of contradictions. Europe legislates altruism under the SoHO Regulation, but without millions of liters of paid U.S. plasma for fractionation, its patients would be left exposed. The “crowding-out” argument? No evidence. Not one death has ever been attributed to compensated plasma programs. On the contrary, where plasma is collected at scale, both paid and voluntary donations thrive side by side.
What does this tell us? That behind the debate, the ethical theatre, and the bipolar dogma, there has only ever been one measure that matters: continuity of care. Patients cannot wait.
This is why we built Global Plasma Supply LTD — not to choose sides in a false argument, but to secure plasma ethically, transparently, and at scale. Because when the medicine reaches the bedside, nobody asks whether it came from Vienna or Texas — they ask whether it arrived in time.
The debate may run circles. The lives do not.
Always think donation.
Always think life.”

Stay updated with Hemostasis Today.
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal